Department of Genetics, University Hospital, Assistance Publique-Hôpitaux de Marseille, INSERM 1104, Aix-Marseille University, Marseille, France.
Groupe Francophone de Cytogénétique Hématologique, Paris, France.
Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.
Multiple cytogenetic subgroups have been described in adult Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL), often comprising small numbers of patients. In this study, we aimed to reassess the prognostic value of cytogenetic abnormalities in a large series of 617 adult patients with Ph-negative BCP-ALL (median age, 38 years), treated in the intensified Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 trials. Combined data from karyotype, DNA index, fluorescence in situ hybridization, and polymerase chain reaction screening for relevant abnormalities were centrally reviewed and were informative in 542 cases (88%), allowing classification in 10 exclusive primary cytogenetic subgroups and in secondary subgroups, including complex and monosomal karyotypes. Prognostic analyses focused on cumulative incidence of failure (including primary refractoriness and relapse), event-free survival, and overall survival. Only 2 subgroups, namely t(4;11)/ and 14q32/ translocations, displayed a significantly worse outcome in this context, still observed after adjustment for age and after censoring patients who received allogeneic stem cell transplantation (SCT) in first remission at SCT time. A worse outcome was also observed in patients with low hypodiploidy/near triploidy, but this was likely related to their higher age and worse tolerance to therapy. The other cytogenetic abnormalities, including complex and monosomal karyotypes, had no prognostic value in these intensive protocols designed for adult patients up to the age of 60 years.
已在成人费城染色体(Ph)阴性 B 细胞前体(BCP)急性淋巴细胞白血病(ALL)中描述了多个细胞遗传学亚组,这些亚组通常包含少数患者。在这项研究中,我们旨在重新评估 617 例成人 Ph 阴性 BCP-ALL 患者(中位年龄 38 岁)的大量系列中细胞遗传学异常的预后价值,这些患者接受了强化成人急性淋巴细胞白血病研究组(GRAALL)-2003/2005 试验的治疗。中心回顾了核型、DNA 指数、荧光原位杂交和聚合酶链反应筛选相关异常的综合数据,并且在 542 例(88%)中有信息可查,允许在 10 个独特的原发性细胞遗传学亚组和继发性亚组中进行分类,包括复杂核型和单体核型。预后分析集中在失败的累积发生率(包括原发性耐药和复发)、无事件生存和总生存。仅 t(4;11)/ 和 14q32/ 易位这 2 个亚组在这种情况下表现出明显更差的结果,在调整年龄后和在将首次缓解时接受异基因干细胞移植(SCT)的患者在 SCT 时间点时排除后仍观察到这种情况。低倍体/近三倍体的预后也较差,但这可能与患者年龄较大且对治疗的耐受性较差有关。其他细胞遗传学异常,包括复杂核型和单体核型,在这些为 60 岁以下成人设计的强化方案中没有预后价值。